Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

✍ Scribed by Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Steven J. Freedman; Boyd B. Scott; Ann Marie Leighton; Patricia A. Watson; Baiteng Zhao; Peter J. O’Dwyer; George Wilding

• Publisher: Springer
• Year: 2010
• Tongue: English
• Weight: 252 KB
• Volume: 67
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-010-1318-9